The drug release kinetics of DDM in acidic (pH 4) conditions demonstrated the feasibility of the DDM formulation in cytoplasmic drug release after CD44 and FR- receptor-mediated endocytosis in BC cells. The gene discussed is CD44; the disease is breast cancer.